Discontinue Besponsa if low platelet count persists for greater than 28 days and is suspected to be related to Besponsa. If prior to Besponsa treatment ANC was less than 1 × 10 9 /L and/or platelet count was less than 50 × 10 9 /L *. The response headers contain information specific to the needs of the response, such as the location (used to redirect the client to a new URI).. Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. Besponsa has been shown to increase the proportion of patients who have complete remission and molecular remission and to delay the progression of disease. The most common side effects are thrombocytopenia, neutropenia, anaemia, leu copenia, infection, haemorrhage and venoocclusive liver disease/sinusoidal obstruction syndrome . The full indication is: " Besponsa is indicated as monotherapy . The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment. B-cell precursor ALL is a type of cancer in which. Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker..